Recherche
Résistance aux traitements et thérapies innovantes : C. Gongora

Liste des Publications

Poinas G, Blache J, Kassab-Chahmi D, Evrard P, Artus P, Alfonsi P, Beaussier M, Cerantola Y, Coloby P, Drapier É, Masson-Lecomt A, Le Normand L, Gamé X, Bosset P, Delaunay L, Fendler J, Ecoffey C, Cuvelier G [Short version of recommendations for enhanced recovery program (ERP) for cystectomy: Technical measures]. Prog. Urol.. 2019;29(2):63-75. doi:10.1016/j.purol.2018.12.002

[Management of patients with systemic treatments]. Prog. Urol.. 2019;29 Suppl 1. doi:10.1016/S1166-7087(19)30169-1

Pignot G, Houede N [Immunotherapy in urology: Concept and results]. Prog. Urol.. Aug 30, 2019. doi:10.1016/j.purol.2019.08.267

Pourquier P [Genetic and transcriptional evolution alters cancer cell line drug response]. Bull Cancer. 2019;106(1):9-10. doi:10.1016/j.bulcan.2018.12.002

Houédé N, Milano G [Care of advanced or metastatic bladder cancer in second line: A specific place for vinflunine]. Bull Cancer. 2019;106(5):431-435. doi:10.1016/j.bulcan.2019.02.007

Mas S, Torro A, Bec N, Erschov G, Gongora C, Larroque C, Martineau P, de Juan A, Marco S Use of physiological information based on grayscale images to improve mass spectrometry imaging data analysis from biological tissues. Anal. Chim. Acta. 2019;1074. doi:10.1016/j.aca.2019.04.074

Flippot R, Dalban C, Laguerre B, Borchiellini D, Négrier S, Chevreau C, Joly F, Geoffrois L, Ladoire S, Mahammedi H, Gross-Goupil M, Deluche E, Priou F, Laramas M, Barthélémy P, Narciso B, Oudard S, Chenot M, Tantot F, Chabaud S, Escudier B, Albiges L Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. J. Clin. Oncol.. 2019;37(23):2008-2016. doi:10.1200/JCO.18.02218

Broudic-Guibert M, Blay J-Y, Vazquez L, Evrard A, Karanian M, Taïeb S, Hoog-Labouret N, Oukhatar C, Boustany-Grenier R, Arnaud A Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report. J Med Case Rep. 2019;13(1):245. doi:10.1186/s13256-019-2140-6

Bersanelli M, Iacovelli R, Buti S, Laguerre B, Procopio G, Lheureux S, Fischer R, Ravaud A, Oudard S, Escudier B, Albiges L, Porta C Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. Eur Urol Oncol. Jul 19, 2019. doi:10.1016/j.euo.2019.06.018

Sgarbura O, Gourgou S, Tosi D, Bakrin N, Bouazza N, Delaine S, Pocard M, Quénet F MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma. Pleura Peritoneum. 2019;4(2):20190010. doi:10.1515/pp-2019-0010

Le Clorennec C, Lazrek Y, Dubreuil O, Sampaio C, Larbouret C, Lanotte R, Poul M-A, Barret J-M, Prost J-F, Pèlegrin A, Chardès T ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells. Cell Commun. Signal. 2019;17(1):106. doi:10.1186/s12964-019-0413-8

Combes E, Andrade A, Tosi D, Michaud H-A, Coquel F, Desigaud D, Jarlier M, Coquelle A, Pasero P, Bonnefoy N, Martineau P, Del Rio M, Beijersbergen R, Vezzio-Vie N Inhibition of Ataxia-Telangiectasia Mutated and RAD3-related (ATR) overcomes oxaliplatin resistance and promotes anti-tumor immunity in colorectal cancer. Cancer Res.. Apr 15, 2019. doi:10.1158/0008-5472.CAN-18-2807

Puszkiel A, Arellano C, Vachoux C, Evrard A, Le Morvan V, Boyer J-C, Robert J, Delmas C, Dalenc F, Debled M, Venat-Bouvet L, Jacot W, Suc E, Sillet-Bach I, Filleron T, Roché H, Chatelut E, White-Koning M, Thomas F Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study. Clin. Pharmacol. Ther.. Feb 20, 2019. doi:10.1002/cpt.1404

Loriot Y, Necchi A, Park S, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa S, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke A Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N. Engl. J. Med.. 2019;381(4):338-348. doi:10.1056/NEJMoa1817323

Oudard S, Latorzeff I, Caty A, Miglianico L, Sevin E, Hardy-Bessard A, Delva R, Mouret L, Priou F, Beuzeboc P, Gravis G, Linassier C, Gomez P, Voog E, Muracciole X, Abraham C, Banu E, Ferrero J-M, Ravaud A, Krakowski I, Lagrange J-L, Deplanque G, Zylberait D, Bozec L, Elaidi R Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial. JAMA Oncol. 2019;5(5):623-632. doi:10.1001/jamaoncol.2018.6607

Guillot A, Joly C, Barthélémy P, Meriaux E, Pouessel D, Chevreau C, Mahammedi H, Roubaud G, Gravis G, Tartas S, Albiges L, Vassal C, Oriol M, Tinquaut F, Espenel S, Bouleftour W, Fizazi K Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study. Clin Genitourin Cancer. 2019;17(1):e38-e43. doi:10.1016/j.clgc.2018.08.006

Fiteni F, Cuenant A, Favier M, Cousin C Clinical Relevance of Routine Monitoring of Patient-reported Outcomes Versus Clinician-reported Outcomes in Oncology. In Vivo. 2019;33(1):17-21. doi:10.21873/invivo.11433

Cherradi S, Martineau P, Gongora C, Del Rio M Claudin gene expression profiles and clinical value in colorectal tumors classified according to their molecular subtype. Cancer Manag Res. 2019;11. doi:10.2147/CMAR.S188192

Corvaglia V, Carbajo D, Prabhakaran P, Ziach K, Mandal P, Santos V, Legeay C, Vogel R, Parissi V, Pourquier P, Huc I Carboxylate-functionalized foldamer inhibitors of HIV-1 integrase and Topoisomerase 1: artificial analogues of DNA mimic proteins. Nucleic Acids Res.. May 10, 2019. doi:10.1093/nar/gkz352

Ragulan C, Eason K, Fontana E, Nyamundanda G, Tarazona N, Patil Y, Poudel P, Lawlor R, Del Rio M, Koo S-L, Tan W-S, Sclafani F, Begum R, Teixeira Mendes L, Martineau P, Scarpa A, Cervantes A, Tan I, Cunningham D, Sadanandam A Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes. Sci Rep. 2019;9(1):7665. doi:10.1038/s41598-019-43492-0

Bourillon L, Bourgier C, Gaborit N, Garambois V, Llès E, Zampieri A, Ogier C, Jarlier M, Radosevic-Robin N, Orsetti B, Delpech H, Theillet C, Colombo P-E, Azria D, Pèlegrin A, Larbouret C, Chardès T An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. Int. J. Cancer. Mar 18, 2019. doi:10.1002/ijc.32273

Pignot G, Roumiguié M, Audenet F, Brunelle S, Colin P, Masson-Lecomte A, Neuzillet Y, Xylinas E, Méjean A [ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology]. Prog. Urol.. Sep 08, 2018. doi:10.1016/j.purol.2018.07.003

Favier M, Bascoul-Mollevi C, Gourgou S, Cousin C, Houédé N [Impacts of routine patient-reported-outcomes monitoring in oncology]. Bull Cancer. Jul 19, 2018. doi:10.1016/j.bulcan.2018.06.010

Pourquier P [How to manipulate DNA repair to generate neoantigens and ameliorate the efficacy of immunotherapies]. Bull Cancer. Aug 23, 2018. doi:10.1016/j.bulcan.2018.07.004

Loriot M-A, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hennart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny A-S, Masskouri F, Boyer J-C, Etienne-Grimaldi M-C [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks]. Bull Cancer. 2018;105(4):397-407. doi:10.1016/j.bulcan.2018.02.001


publications

Poinas G, Blache J, Kassab-Chahmi D, Evrard P, Artus P, Alfonsi P, Beaussier M, Cerantola Y, Coloby P, Drapier É, Masson-Lecomt A, Le Normand L, Gamé X, Bosset P, Delaunay L, Fendler J, Ecoffey C, Cuvelier G [Short version of recommendations for enhanced recovery program (ERP) for cystectomy: Technical measures]. Prog. Urol.. 2019;29(2):63-75. doi:10.1016/j.purol.2018.12.002

[Management of patients with systemic treatments]. Prog. Urol.. 2019;29 Suppl 1. doi:10.1016/S1166-7087(19)30169-1

Pignot G, Houede N [Immunotherapy in urology: Concept and results]. Prog. Urol.. Aug 30, 2019. doi:10.1016/j.purol.2019.08.267

Pourquier P [Genetic and transcriptional evolution alters cancer cell line drug response]. Bull Cancer. 2019;106(1):9-10. doi:10.1016/j.bulcan.2018.12.002

Houédé N, Milano G [Care of advanced or metastatic bladder cancer in second line: A specific place for vinflunine]. Bull Cancer. 2019;106(5):431-435. doi:10.1016/j.bulcan.2019.02.007

Mas S, Torro A, Bec N, Erschov G, Gongora C, Larroque C, Martineau P, de Juan A, Marco S Use of physiological information based on grayscale images to improve mass spectrometry imaging data analysis from biological tissues. Anal. Chim. Acta. 2019;1074. doi:10.1016/j.aca.2019.04.074

Flippot R, Dalban C, Laguerre B, Borchiellini D, Négrier S, Chevreau C, Joly F, Geoffrois L, Ladoire S, Mahammedi H, Gross-Goupil M, Deluche E, Priou F, Laramas M, Barthélémy P, Narciso B, Oudard S, Chenot M, Tantot F, Chabaud S, Escudier B, Albiges L Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. J. Clin. Oncol.. 2019;37(23):2008-2016. doi:10.1200/JCO.18.02218

Broudic-Guibert M, Blay J-Y, Vazquez L, Evrard A, Karanian M, Taïeb S, Hoog-Labouret N, Oukhatar C, Boustany-Grenier R, Arnaud A Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report. J Med Case Rep. 2019;13(1):245. doi:10.1186/s13256-019-2140-6

Bersanelli M, Iacovelli R, Buti S, Laguerre B, Procopio G, Lheureux S, Fischer R, Ravaud A, Oudard S, Escudier B, Albiges L, Porta C Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. Eur Urol Oncol. Jul 19, 2019. doi:10.1016/j.euo.2019.06.018

Sgarbura O, Gourgou S, Tosi D, Bakrin N, Bouazza N, Delaine S, Pocard M, Quénet F MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma. Pleura Peritoneum. 2019;4(2):20190010. doi:10.1515/pp-2019-0010

Le Clorennec C, Lazrek Y, Dubreuil O, Sampaio C, Larbouret C, Lanotte R, Poul M-A, Barret J-M, Prost J-F, Pèlegrin A, Chardès T ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells. Cell Commun. Signal. 2019;17(1):106. doi:10.1186/s12964-019-0413-8

Combes E, Andrade A, Tosi D, Michaud H-A, Coquel F, Desigaud D, Jarlier M, Coquelle A, Pasero P, Bonnefoy N, Martineau P, Del Rio M, Beijersbergen R, Vezzio-Vie N Inhibition of Ataxia-Telangiectasia Mutated and RAD3-related (ATR) overcomes oxaliplatin resistance and promotes anti-tumor immunity in colorectal cancer. Cancer Res.. Apr 15, 2019. doi:10.1158/0008-5472.CAN-18-2807

Puszkiel A, Arellano C, Vachoux C, Evrard A, Le Morvan V, Boyer J-C, Robert J, Delmas C, Dalenc F, Debled M, Venat-Bouvet L, Jacot W, Suc E, Sillet-Bach I, Filleron T, Roché H, Chatelut E, White-Koning M, Thomas F Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study. Clin. Pharmacol. Ther.. Feb 20, 2019. doi:10.1002/cpt.1404

Loriot Y, Necchi A, Park S, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa S, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke A Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N. Engl. J. Med.. 2019;381(4):338-348. doi:10.1056/NEJMoa1817323

Oudard S, Latorzeff I, Caty A, Miglianico L, Sevin E, Hardy-Bessard A, Delva R, Mouret L, Priou F, Beuzeboc P, Gravis G, Linassier C, Gomez P, Voog E, Muracciole X, Abraham C, Banu E, Ferrero J-M, Ravaud A, Krakowski I, Lagrange J-L, Deplanque G, Zylberait D, Bozec L, Elaidi R Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial. JAMA Oncol. 2019;5(5):623-632. doi:10.1001/jamaoncol.2018.6607

Guillot A, Joly C, Barthélémy P, Meriaux E, Pouessel D, Chevreau C, Mahammedi H, Roubaud G, Gravis G, Tartas S, Albiges L, Vassal C, Oriol M, Tinquaut F, Espenel S, Bouleftour W, Fizazi K Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study. Clin Genitourin Cancer. 2019;17(1):e38-e43. doi:10.1016/j.clgc.2018.08.006

Fiteni F, Cuenant A, Favier M, Cousin C Clinical Relevance of Routine Monitoring of Patient-reported Outcomes Versus Clinician-reported Outcomes in Oncology. In Vivo. 2019;33(1):17-21. doi:10.21873/invivo.11433

Cherradi S, Martineau P, Gongora C, Del Rio M Claudin gene expression profiles and clinical value in colorectal tumors classified according to their molecular subtype. Cancer Manag Res. 2019;11. doi:10.2147/CMAR.S188192

Corvaglia V, Carbajo D, Prabhakaran P, Ziach K, Mandal P, Santos V, Legeay C, Vogel R, Parissi V, Pourquier P, Huc I Carboxylate-functionalized foldamer inhibitors of HIV-1 integrase and Topoisomerase 1: artificial analogues of DNA mimic proteins. Nucleic Acids Res.. May 10, 2019. doi:10.1093/nar/gkz352

Ragulan C, Eason K, Fontana E, Nyamundanda G, Tarazona N, Patil Y, Poudel P, Lawlor R, Del Rio M, Koo S-L, Tan W-S, Sclafani F, Begum R, Teixeira Mendes L, Martineau P, Scarpa A, Cervantes A, Tan I, Cunningham D, Sadanandam A Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes. Sci Rep. 2019;9(1):7665. doi:10.1038/s41598-019-43492-0

Bourillon L, Bourgier C, Gaborit N, Garambois V, Llès E, Zampieri A, Ogier C, Jarlier M, Radosevic-Robin N, Orsetti B, Delpech H, Theillet C, Colombo P-E, Azria D, Pèlegrin A, Larbouret C, Chardès T An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. Int. J. Cancer. Mar 18, 2019. doi:10.1002/ijc.32273

Pignot G, Roumiguié M, Audenet F, Brunelle S, Colin P, Masson-Lecomte A, Neuzillet Y, Xylinas E, Méjean A [ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology]. Prog. Urol.. Sep 08, 2018. doi:10.1016/j.purol.2018.07.003

Favier M, Bascoul-Mollevi C, Gourgou S, Cousin C, Houédé N [Impacts of routine patient-reported-outcomes monitoring in oncology]. Bull Cancer. Jul 19, 2018. doi:10.1016/j.bulcan.2018.06.010

Pourquier P [How to manipulate DNA repair to generate neoantigens and ameliorate the efficacy of immunotherapies]. Bull Cancer. Aug 23, 2018. doi:10.1016/j.bulcan.2018.07.004

Loriot M-A, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hennart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny A-S, Masskouri F, Boyer J-C, Etienne-Grimaldi M-C [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks]. Bull Cancer. 2018;105(4):397-407. doi:10.1016/j.bulcan.2018.02.001



© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés